Cox univariate analyses and Cox multivariate analyses for
different factors
A total of 65 out of 127 patients with treated metastatic advanced
colorectal cancer who received immune checkpoint inhibitors were
followed up. Age (≤60 vs. >60), gender (Female vs. Male),
tumor site (Left colon vs. Right colon), MMR (pMMR vs. dMMR), KRAS
status (KRAS mutant vs. KRAS wild), whether combined with targeted
therapy (No vs. Yes ), whether liver metastatic cancer (No vs.Yes),
whether lymph nodes metastases (No vs.Yes), type of immune checkpoint
inhibitor (Domestic vs. Imported), and level of NLR (<3 vs.≥3)
were used to perform Cox one-way survival analysis. The results showed
that there was a statistically significant difference in PFS between the
different groups of patients with MMR status and NLR level factors,P <0.05, and no statistically significant difference in
the other factors. The MMR and NLR level factors were then included in
Cox multivariate survival analysis, and the results showed that there
was a statistically significant difference in the PFS data between the
patients in the high NLR group and the low NLR group, P =0.024,
which further illustrated that patients with a low NLR who received
immune checkpoint inhibitor therapy had a longer PFS and a better
prognosis, as shown in Table 5.
Table 5 Cox analyses for different factors